OncoMatch/Clinical Trials/NCT05760378
Famitinib in Combination With Camrelizumab and TPC in The First-line Treatment of Immunomodulatory Locally Advanced or Metastatic TNBC.
Is NCT05760378 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including Famitinib and Camrelizumab for triple-negative breast cancer.
Treatment: Famitinib · Camrelizumab · nab-Palitaxel/Capecitabine/Eribulin Mesylate/Carboplatin — The study is being conducted to evaluate the Famitinib with Camrelizumab plus treatment of physician's choice (TPC) versus Camrelizumab plus TPC in Patients with Unresectable Locally Advanced or Metastatic Immunomodulatory Triple Negative Breast Cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Triple-Negative Breast Cancer
Breast Carcinoma
Biomarker criteria
Required: HER2 (ERBB2) wild-type
Required: ESR1 wild-type
Required: PR (PGR) wild-type
Disease stage
Required: Stage IV, III
Metastatic disease required
Cancer stage: recurrent or metastatic breast cancer; Local recurrence be confirmed by the researchers could not be radical resection.
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: VEGFR inhibitor (famitinib, sorafenib, sunitinib, regorafenib)
Previous received anti-VEGFR small molecule tyrosine kinase inhibitors (e.g. famitinib, sorafenib, Sunitinib, regorafenib, etc.) for treatment of the patients
Lab requirements
Blood counts
Adequate hematologic function, laboratory test results.
Kidney function
Adequate end-organ function, laboratory test results.
Liver function
Adequate end-organ function, laboratory test results.
Adequate hematologic and end-organ function, laboratory test results.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify